8-K
CV Sciences, Inc. (CVSI)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 26, 2026
CV SCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 000-54677 | 80-0944970 |
|---|---|---|
| (State or Other Jurisdiction<br><br>of Incorporation) | (Commission File Number) | (IRS Employer<br><br>Identification No.) |
| 9530 Padgett Street, Suite 107<br><br>San Diego, California | 92126 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (866) 290-2157
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br>Symbol(s) | Name of each exchange on which registered |
|---|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Conditions
The information provided below in "Item 7.01 - Regulation FD Disclosure" of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure
On March 26, 2026, CV Sciences, Inc. (the "Company") issued a press release regarding the Company’s financial results for its fiscal year and quarter ended December 31, 2025. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference. The press release includes non-GAAP financial measures as defined in Regulation G. The press release also includes a presentation of the most directly comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the United States (GAAP), information reconciling the non-GAAP financial measures to the GAAP financial measures and a discussion of the reasons why the Company’s management believes that presentation of the non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations. The non-GAAP financial measures presented therein should be considered in addition to, not as a substitute for, or superior to, financial measures calculated and presented in accordance with GAAP.
Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements.
The information set forth under Item 7.01 of this Current Report on Form 8-K (“Current Report”), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit<br><br>Number | Description |
|---|---|
| 99.1 | Press Release of CV Sciences, Inc. dated March 26, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CV SCIENCES, INC. | ||
|---|---|---|
| Date: March 26, 2026 | By: | /s/ Joseph Dowling |
| Joseph Dowling | ||
| Chief Executive Officer |
EX-99.1
Exhibit 99.1
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
San Diego, CA - March 26, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2025.
Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights
- Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for the third quarter 2025;
- Recognized gross margin of 49.0% for fiscal 2025, a significant improvement from 45.6% for 2024; Gross margin of 50.5% for the fourth quarter 2025 compared to 43.2% for the fourth quarter 2024 and 48.5% for the third quarter 2025;
- Cash balance of $0.3 million at year end compared to $0.5 million at the end of 2024;
- Reduced operating expenses by 17.2% to $7.7 million for fiscal 2025 compared to $9.4 million for 2024, excluding benefit from reversal of accrued payroll taxes;
- Recognized an adjusted EBITDA loss of $0.3 million for fiscal 2025 compared to $0.8 million for 2024; Recognized positive adjusted EBITDA of $0.1 million for the fourth quarter 2025, significantly improved from adjusted EBITDA losses of $0.4 million for the fourth quarter 2024 and $0.1 million for the third quarter 2025;
- Expanded +PlusCBD™ product offering with the launch of Ignite, a men's performance formula for vitality, recovery, libido and focus (Q3 2025); and
- Launched EMPOWR, a plant-based protein and creatine formula designed for total wellness (Q1 2026), and
- Completed successful debt restructuring designed to strengthen financial position and fuel future growth (Q1 2026).
“We made meaningful progress in 2025 executing against our top priorities of improving margins, reducing our cost structure, and moving the business toward sustainable profitability. Our gross margin expansion and significant reduction in operating expenses drove a substantial improvement in adjusted EBITDA, culminating in positive adjusted EBITDA in the fourth quarter,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “As we enter 2026, we are building on this momentum by further enhancing operating efficiency and driving consistent positive cash flow. At the same time, we see a compelling opportunity to accelerate growth through disciplined, strategic acquisitions that complement our existing portfolio and leverage our operational platform. We believe this balanced approach—combining near-term profitability with targeted M&A—positions CV Sciences to deliver improved financial performance and long-term shareholder value.”
Operating Results - Full Year 2025 Compared to Full Year 2024
Sales for fiscal 2025 were $13.8 million, a decrease of 12.2% from $15.7 million in 2024. The decline is driven by lower sales volume due to temporary out-of-stock issues for some of our key products and restrictive regulations at the federal level and in certain states. The total number of units sold during fiscal 2025 decreased by 12.6%, partially offset by minor increases in average sales prices. In addition, 39% of our net revenue for the year ended December 31, 2025 was from new products launched since January 1, 2023. During this time period, we launched 39 new products.
We generated an operating loss of $0.5 million in fiscal 2025 significantly reduced from $2.2 million in 2024. The lower operating loss is mostly due to reduced operating expenses across the business. We had negative adjusted EBITDA of $0.3 million for fiscal 2025, also significantly improved from $0.8 million in 2024. The improvement is mostly due to lower operating expenses.
Fourth Quarter 2025 Results
During the fourth quarter of 2025, sales increased by 1.6% to $3.3 million compared to the third quarter of 2025. The sequential increase in sales is mostly due to additional B2B revenue. We generated an operating loss of $0.1 million in the fourth quarter of 2025, compared to operating losses of $0.6 million in the fourth quarter of 2024 and $0.3 million in the third quarter of 2025. The Company had a positive adjusted EBITDA of $0.1 million in the fourth quarter of 2025, compared to negative adjusted EBITDA of $0.4 million in the fourth quarter of 2024 and $0.1 million in the third quarter of 2025.
Conference Call and Webcast
The Company will host a conference call and webcast to discuss these results today at 4:30 pm EDT/1:30 pm PDT. The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1754173&tp_key=c94416da11. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. A telephone replay will be available approximately three hours after the call concludes, and will be available through Thursday, April 2, 2026, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13759006.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
Forward Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
Contact Information
ir@cvsciences.com
CV SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(in thousands, except per share data)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Product sales, net | $ | 3,307 | $ | 3,884 | $ | 13,789 | $ | 15,705 | ||||
| Cost of goods sold | 1,636 | 2,207 | 7,037 | 8,537 | ||||||||
| Gross profit | 1,671 | 1,677 | 6,752 | 7,168 | ||||||||
| Operating expenses: | ||||||||||||
| Research and development | 18 | 25 | 122 | 118 | ||||||||
| Selling, general and administrative | 1,728 | 2,298 | 7,622 | 9,240 | ||||||||
| Benefit from reversal of accrued payroll taxes | — | — | (522 | ) | — | |||||||
| Total operating expenses | 1,746 | 2,323 | 7,222 | 9,358 | ||||||||
| Operating loss | (75 | ) | (646 | ) | (470 | ) | (2,190 | ) | ||||
| Gain on extinguishment of debt | — | — | (38 | ) | — | |||||||
| Interest expense, net | 129 | 94 | 517 | 212 | ||||||||
| Loss before income taxes | (204 | ) | (740 | ) | (949 | ) | (2,402 | ) | ||||
| Income tax expense (benefit) | 2 | (14 | ) | 9 | (8 | ) | ||||||
| Net loss | $ | (206 | ) | $ | (726 | ) | $ | (958 | ) | $ | (2,394 | ) |
| Weighted average common shares outstanding, basic and diluted | 184,264 | 184,264 | 184,264 | 175,585 | ||||||||
| Net loss per common share, basic and diluted | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.01 | ) | $ | (0.01 | ) |
CV SCIENCES, INC.
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except per share data)
| December 31, 2024 | |||||
|---|---|---|---|---|---|
| Assets | |||||
| Current assets: | |||||
| Cash | 278 | $ | 454 | ||
| Accounts receivable, net | 402 | 522 | |||
| Inventory | 4,087 | 4,897 | |||
| Prepaid expenses and other | 366 | 370 | |||
| Total current assets | 5,133 | 6,243 | |||
| Property and equipment, net | 344 | 399 | |||
| Right of use assets | 347 | 94 | |||
| Intangibles, net | 76 | 93 | |||
| Goodwill | 1,015 | 971 | |||
| Other assets | 47 | 127 | |||
| Total assets | 6,962 | $ | 7,927 | ||
| Liabilities and stockholders' equity | |||||
| Current liabilities: | |||||
| Accounts payable | 1,044 | $ | 1,925 | ||
| Accrued expenses | 2,447 | 3,424 | |||
| Current portion of operating lease liability | 247 | 83 | |||
| Current portion of long-term debt, net of discounts and issuance costs | 1,262 | 677 | |||
| Total current liabilities | 5,000 | 6,109 | |||
| Operating lease liability | 100 | 19 | |||
| Debt, net of discounts and issuance costs | 387 | — | |||
| Deferred tax liability | 7 | 4 | |||
| Total liabilities | 5,494 | 6,132 | |||
| Commitments and contingencies | |||||
| Stockholders' equity | |||||
| Preferred stock, par value 0.0001; 10,000 shares authorized; 1 shares issued as of December 31, 2025 and December 31, 2024; and no shares outstanding as of December 31, 2025 and December 31, 2024 | — | — | |||
| Common stock, par value 0.0001; 790,000 shares authorized as of December 31, 2025 and December 31, 2024; 184,264 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 18 | 18 | |||
| Additional paid-in capital | 89,330 | 88,773 | |||
| Accumulated deficit | (87,939 | ) | (86,981 | ) | |
| Accumulated other comprehensive income (loss) | 59 | (15 | ) | ||
| Total stockholders' equity | 1,468 | 1,795 | |||
| Total liabilities and stockholders' equity | 6,962 | $ | 7,927 |
All values are in US Dollars.
CV SCIENCES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)
| Year Ended December 31, | ||||||
|---|---|---|---|---|---|---|
| 2025 | 2024 | |||||
| OPERATING ACTIVITIES | ||||||
| Net loss | $ | (958 | ) | $ | (2,394 | ) |
| Adjustments to reconcile net loss to net cash flows used in operating activities: | ||||||
| Depreciation and amortization | 192 | 334 | ||||
| Stock-based compensation | 497 | 258 | ||||
| Amortization of debt discount | 513 | 209 | ||||
| Amortization of right of use assets | 238 | 122 | ||||
| Gain in fair value of contingent consideration liabilities | — | (188 | ) | |||
| Gain on debt extinguishment | (38 | ) | — | |||
| Benefit from reversal of accrued payroll tax | (522 | ) | — | |||
| Deferred taxes | 3 | (15 | ) | |||
| Other | 138 | 355 | ||||
| Change in operating assets and liabilities: | ||||||
| Accounts receivable, net | 124 | (84 | ) | |||
| Inventory | 827 | 803 | ||||
| Prepaid expenses and other | 166 | 342 | ||||
| Accounts payable and accrued expenses | (1,342 | ) | (467 | ) | ||
| Operating lease liability | (245 | ) | (136 | ) | ||
| Net cash flows used in operating activities | (407 | ) | (861 | ) | ||
| INVESTING ACTIVITIES | ||||||
| Purchases of property and equipment | (109 | ) | (18 | ) | ||
| Acquisition of business, net of cash acquired | — | (10 | ) | |||
| Net cash flows used in investing activities | (109 | ) | (28 | ) | ||
| FINANCING ACTIVITIES | ||||||
| Proceeds from note payable | 1,650 | 900 | ||||
| Debt issuance costs related to note payable | (90 | ) | (5 | ) | ||
| Repayment of note payable | (1,050 | ) | (622 | ) | ||
| Repayment of unsecured debt | (173 | ) | (241 | ) | ||
| Net cash flows provided by financing activities | 337 | 32 | ||||
| Effect of exchange rate changes on cash | 3 | (6 | ) | |||
| Net decrease in cash | (176 | ) | (863 | ) | ||
| Cash, beginning of year | 454 | 1,317 | ||||
| Cash, end of year | 278 | 454 | ||||
| Supplemental cash flow disclosures: | ||||||
| Interest paid | $ | 6 | $ | 8 | ||
| Supplemental disclosure of non-cash transactions: | ||||||
| Purchase of insurance through issuance of note payable | $ | 160 | $ | 177 | ||
| Right of use asset financed by lease liabilities | $ | 486 | $ | 49 | ||
| Debt issuance cost for note payable | $ | (550 | ) | $ | (284 | ) |
| Services paid with common stock | $ | 60 | $ | 182 | ||
| Fair value of assets acquired, excluding cash | $ | — | $ | 414 | ||
| Liabilities assumed | — | (73 | ) | |||
| Goodwill on acquisition | — | 640 | ||||
| Common stock consideration | — | (871 | ) | |||
| Contingent consideration | — | (100 | ) | |||
| Cash paid for acquisition | $ | — | $ | 10 |
CV SCIENCES, INC.
NON-GAAP FINANCIAL MEASURES (UNAUDITED)
We prepare our consolidated financial statements in accordance with generally accepted accounting principles for the United States (GAAP). The non-GAAP financial measures, such as net income (loss) per share and Adjusted EBITDA included in this press release are different from those otherwise presented under GAAP. We use non-GAAP measures internally to evaluate our performance and make financial and operational decisions that are presented in a manner that adjusts from their equivalent GAAP measures or that supplement the information provided by our GAAP measures. The non-GAAP financial measures exclude non-cash compensation expense for stock options. When evaluating the performance of our business and developing short and long-term plans, we do not consider share-based compensation charges. Although share-based compensation is necessary to attract and retain quality employees, our consideration of share-based compensation places its primary emphasis on overall shareholder dilution rather than the accounting charges associated with such grants. Because of the varying availability of valuation methodologies and subjective assumptions, we believe that the exclusion of share-based compensation allows for more accurate comparison of our financial results to previous periods. In addition, we believe it useful to investors to understand the specific impact of the application of the fair value method of accounting for share-based compensation on our operating results.
Adjusted EBITDA is defined by us as EBITDA (net loss plus depreciation, amortization, interest, and income tax expense, less income tax benefit, further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We use Adjusted EBITDA because we believe it more clearly highlights trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures, since Adjusted EBITDA eliminates from our results specific financial items that have less bearing on our core operating performance.
We use Adjusted EBITDA in communicating certain aspects of our results and performance, including in this press release, and believe that Adjusted EBITDA, when viewed in conjunction with our GAAP results and the accompanying reconciliation, can provide investors with greater transparency and a greater understanding of factors affecting our financial condition and results of operations than GAAP measures alone. In addition, we believe the presentation of Adjusted EBITDA is useful to investors in making period-to-period comparison of results because the adjustments to GAAP are not reflective of our core business performance.
A reconciliation from our GAAP net loss to non-GAAP net income (loss) for the three months and year ended December 31, 2025 and 2024 is detailed below (in thousands, except per share data):
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Net loss - GAAP | $ | (206 | ) | $ | (726 | ) | $ | (958 | ) | $ | (2,394 | ) |
| Stock-based compensation (1) | 123 | 104 | 497 | 258 | ||||||||
| Professional fees associated with legal dispute (2) | — | 55 | — | 828 | ||||||||
| Benefit from reversal of accrued payroll tax (3) | — | — | (522 | ) | — | |||||||
| Note discount and interest expense (4) | 129 | 94 | 517 | 212 | ||||||||
| Net income (loss) - non-GAAP | $ | 46 | $ | (473 | ) | $ | (466 | ) | $ | (1,096 | ) | |
| Diluted EPS - GAAP | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.01 | ) | $ | (0.01 | ) |
| Stock-based compensation (1) | — | — | — | — | ||||||||
| Professional fees associated with legal dispute (2) | — | — | — | — | ||||||||
| Benefit from reversal of accrued payroll tax (3) | — | — | — | — | ||||||||
| Note discount and interest expense (4) | — | — | 0.01 | — | ||||||||
| Diluted EPS - non-GAAP | $ | 0.00 | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.01 | ) | |
| Shares used to calculate diluted EPS - GAAP and non-GAAP | 184,264 | 184,264 | 184,264 | 175,585 |
- Represents stock-based compensation expense related to stock options awarded to employees and non-executive directors based on the grant date fair value using the Black-Scholes valuation model.
- Represents legal and other professional expenses incurred during 2024 associated with the legal dispute with founder.
- Represents benefit from reversal of accrued payroll tax associated with RSU release to founder in 2019.
- Represents amortization of OID/debt issuance costs for notes payable and interest expense.
A reconciliation from our net loss to Adjusted EBITDA, a non-GAAP measure, for the three months and year ended December 31, 2025 and 2024 is detailed below (in thousands):
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Net loss | $ | (206 | ) | $ | (726 | ) | $ | (958 | ) | $ | (2,394 | ) |
| Depreciation expense | 13 | 90 | 168 | 313 | ||||||||
| Amortization expense | 6 | 6 | 24 | 21 | ||||||||
| Interest expense | 129 | 94 | 517 | 212 | ||||||||
| Income tax expense (benefit) | 2 | (14 | ) | 9 | (8 | ) | ||||||
| EBITDA | (56 | ) | (550 | ) | (240 | ) | (1,856 | ) | ||||
| Stock-based compensation (1) | 123 | 104 | 497 | 258 | ||||||||
| Professional fees associated with legal dispute (2) | — | 55 | — | 828 | ||||||||
| Gain on debt extinguishment (3) | — | — | (38 | ) | — | |||||||
| Benefit from reversal of accrued payroll tax (4) | — | — | (522 | ) | — | |||||||
| Adjusted EBITDA | $ | 67 | $ | (391 | ) | $ | (303 | ) | $ | (770 | ) |
- Represents stock-based compensation expense related to stock options awarded to employees and non-executive directors based on the grant date fair value using the Black-Scholes valuation model.
- Represents legal and other professional expenses incurred during 2024 associated with the legal dispute with founder.
- Represents gain on extinguishment of debt related to our Streeterville note payable.
- Represents benefit from reversal of accrued payroll tax associated with RSU release to founder in 2019.